Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 6:11:2145-2149.
doi: 10.2147/OPTH.S151933. eCollection 2017.

Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy

Nadeem Ali Dhirani  1 , Yelin Yang  2 , Sohel Somani  2   3   4
Affiliations

Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy

Nadeem Ali Dhirani et al. Clin Ophthalmol. .

Abstract

Objective: To evaluate the short- and long-term outcomes of half-dose verteporfin with photodynamic therapy (PDT) in the treatment of chronic central serous retinopathy (CSR).

Design: Retrospective case series.

Participants: 45 eyes in 39 patients with chronic CSR were included. Diagnosis of chronic CSR was confirmed by fluorescein angiography and persistence of subretinal fluid by optical coherence tomography for a minimum of 3 months duration.

Methods: Each patient underwent treatment with half-dose verteporfin with full-fluence PDT; initial follow-up was defined as a 6-8 week visit following the treatment, and final follow-up ranged from 5 to 70 months.

Results: The average follow-up period for treatment was 19.3 months. Best-corrected visual acuity increased from logMAR means of 0.52 to 0.42 (p<0.05). Central retinal thickness and choroidal thickness also significantly decreased at last follow-up (p<0.05). Eight of 45 eyes (18%) demonstrated a recurrence of CSR following treatment within the follow-up period. At the final follow-up, 41 out of the 45 eyes (91%) had complete resolution of subretinal fluid accumulation.

Conclusion: Half-dose PDT is an effective treatment option for chronic CSR in a Canadian population, and it is both safe and durable. The positive treatment effect is realized rapidly, with the initial 6-week result highly correlated with the final follow-up result.

Keywords: central serous chorioretinopathy; half-dose verteporfin; photodynamic therapy; verteporfin.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Mean BCVA at baseline and both follow-ups, showing significant improvement over time. Note: Error bars represent standard errors of the mean. Abbreviation: BCVA, best-corrected visual acuity.
Figure 2
Figure 2
Resolution of subretinal fluid with treatment over time. Abbreviations: PDT, photodynamic therapy; SRF, subretinal fluid.
Figure 3
Figure 3
Mean central retinal thickness at baseline and both follow-ups, showing significant reduction with treatment. Abbreviation: CRT, central retinal thickness.
Figure 4
Figure 4
Mean choroidal thickness at baseline and both follow-ups, showing significant reduction with treatment. Abbreviation: CT, choroidal thickness.
See this image and copyright information in PMC

References

    1. Piccolino FC, Borgia L, Zinicola E, Zingirian M. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye (Lond) 1995;9(Pt 3):324–332. - PubMed
    1. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–126. - PMC - PubMed
    1. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013;41(2):201–214. - PubMed
    1. Wang M, Munch IC, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126–145. - PubMed
    1. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials – TAP report. treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol. 1999;117(10):1329–1345. - PubMed

LinkOut - more resources